Substance
ID:544
Names and Identifiers
Brand Name
CardiaguttDignoverNovo-VeramilUniverVasolanBerkatensCalan SRCovera-HSDilacoranVeraptinVeracimVerelanVerelan PMCalanIproveratrilIsoptimoIsoptinIsoptin SRNU-VerapQuasarApo-VerapArpamylCardibeltinCordiloxGeanginDrosteakardSecuronVeramexVerexamil
Synonyms
Verapamil [Usan:Ban:Inn]Verapamilo [INN-Spanish]Verapamilum [INN-Latin]Verapamil HClVerapamil
IUPAC name
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
IUPAC Traditional name
verapamil
Properties
Physical Property
Solubility
4.47 mg/L
Hydrophobicity(logP)
4.7
Molecule Details
Drug Groups
approved
Description
A calcium channel blocker that is a class IV anti-arrhythmia agent. [PubChem]
Indication
For the treatment of hypertension, angina, and cluster headache prophylaxis.
Pharmacology
Verapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.
Toxicity
LD50=8 mg/kg (i.v. in mice)
Affected Organisms
Humans and other mammals
Absorption
90%
Half Life
2.8-7.4 hours
Protein Binding
90%
Elimination
Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.
References
•
Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83.
[Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. Pubmed